7-bromo-2-tert-butyltetralin-1-one | 1257832-90-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 7-bromo-2-tert-butyltetralin-1-one
• 英文别名: 7-bromo-2-tert-butyl-3,4-dihydro-2H-naphthalen-1-one；7-Bromo-2-(tert-butyl)-3,4-dihydronaphthalen-1(2H)-one
• CAS: 1257832-90-8
• 化学式: C₁₄H₁₇BrO
• 分子量: 281.192
• InChiKey: JMTHKRVZPKXSOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-bromo-2-tert-butyltetralin-1-one 在 溴 、 溶剂黄146 作用下， 反应 3.83h， 以100%的产率得到2,7-dibromo-2-tert-butyltetralin-1-one
  参考文献：
  名称：

  HETEROCYCLIC ANTIVIRAL COMPOUNDS

  摘要：

  具有化学式I的化合物，其中R1、R2、R3、R4、X1、X2、X3和X4如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了治疗HCV感染和抑制HCV复制的组合物和方法。

  公开号：

  US20100311760A1
• 作为产物：
  描述：

  7-溴-3,4-二氢萘-1(2H)-酮 在 四氯化钛 、 三乙胺 、 sodium iodide 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 72.5h， 生成 7-bromo-2-tert-butyltetralin-1-one
  参考文献：
  名称：

  Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase

  摘要：

  In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,8-tetrasubstituted quinoline core was identified as replacement of the stilbene moiety. 6-Methoxy-2(1H)-pyridone was identified among several heterocyclic headgroups to have the best potency. Solubility of the template was improved by replacing a planar aryl linker with a saturated pyrrolidine. Profiling of the most promising compounds led to the identification of quinoline 41 (RG7109), which was selected for advancement to clinical development.

  DOI：

  10.1021/jm401329s

文献信息

• Quinoline inhibitors of HCV polymerase
  申请人：Roche Palo Alto LLC

  公开号：US08026253B2

  公开（公告）日：2011-09-27

  Compounds having the formula I wherein wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  公式为I的化合物，其中R1，R2，R3，R4，X1，X2，X3和X4如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还披露了治疗HCV感染和抑制HCV复制的组合物和方法。
• Quinoline inhibitors of hepatitis C virus polymerase
  申请人：de Vicente Fidalgo Javier

  公开号：US08487103B2

  公开（公告）日：2013-07-16

  Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein

  使用式I中的化合物治疗HCV感染和抑制HCV复制的方法，其中R1，R2，R3，R4，X1，X2，X3和X4如本文所定义。
• US8026253B2
  申请人：——

  公开号：US8026253B2

  公开（公告）日：2011-09-27
• US8487103B2
  申请人：——

  公开号：US8487103B2

  公开（公告）日：2013-07-16
• [EN] HETEROCYCLIC ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010142656A1

  公开（公告）日：2010-12-16

  Compounds having the formula (I) wherein wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.